Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR [U43/U44])

The summary for the Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR [U43/U44]) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR [U43/U44])
	CFDA Number:	93.393
	CFDA Description:	Cancer Cause and Prevention Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Education Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PAR-10-286
	Document Type:	Grants Notice
	Funding Instrument Type:	Cooperative Agreement
	Posted Date:	Sep 21, 2010
	Creation Date:	Sep 21, 2010
	Original Closing Date for Applications:	Jul 08, 2013
	Current Closing Date for Applications:	Jul 08, 2013
	Archive Date:	Aug 08, 2013
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	$150,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Information not provided
Grant Description: Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/par-10-286.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Alliance of Glycobiologists for Detection of Cancer (U01); • Cancer Target Discovery and Development (CTDD) Network (U01); • Community Clinical Oncology Program Research Bases (U10); • Minority-Based Community Clinical Oncology Program Groups (U10); • Community Clinical Oncology Program Groups (U10); • Pilot Studies in Pancreatic Cancer; • CANCER PREVENTION RESEARCH SMALL GRANT PROGRAM; • MOLECULAR TARGETS FOR NUTRIENTS IN PROSTATE CANCER PREVENTION; • Cancer Prevention Research Small Grant Program (R03); • Pilot Studies in Pancreatic Cancer (R03)